Comirnaty
Overview
The mRNA COVID-19 vaccine (BNT162b2 / tozinameran) co-developed and commercialized with Pfizer - the first mRNA vaccine authorized for human use and the product that validated the platform at global scale.
Marketed globally as an updated seasonal COVID-19 vaccine; the XFG-adapted formulation is now authorized in the EU (July 29, 2026), the US (FDA approval August 27, 2026, for adults 65+ and higher-risk 5-64 year-olds), and Canada (Health Canada authorization September 17, 2026, for ages 6 months and older, with inventory due in the coming days and weeks). Still BioNTech's primary revenue driver, but sales have collapsed faster than guided - Q2 2026 revenue was just €105.6M - driving the August 2026 guidance cut and the manufacturing-network pullback.